Clinical Trial Search

Primary: Number of Participants With the Change in Blood Pressure (Both Systolic and Diastolic) Under the Treatment of NIfedipine 30mg XL Versus Placebo — 18; 27 Participants

Primary: Mean Systolic Blood Pressure During Hour After Study Drug — 147; 152 mmHg

Primary: Proportion of Participants With Recorded Blood Pressure Values in Office — 43; 44; 49; 56 Participants

Primary: Change in Pulsatility Index (PI) — -0.56; -0.53; -0.43; -0.88 ratio

Primary: Duration of Severe-range Hypertension After Delivery — 38.0; 35.3 hours — p=0.3

Primary: Renal Function in Severe Preeclampsia With Restrictive Fluid Therapy — 0.69; 0.73; 0.99; 0.93 mg/dl — p=<0.05

Primary: Preeclampsia — 169; 156 Participants — p=0.37

Primary: Microvascular Endothelial Function (Cutaneous Conductance, %Maximum) — 95; 77 % of maximal cutaneous conductance

Primary: Number of Participants With Persistent Postpartum Hypertension Defined as Systolic Blood Pressure ≥ 150 and/or Diastolic Blood Pressure ≥ 100 mmHg — 26; 34 Participants

Primary: Incidence of Preterm (<37 Weeks) Preeclampsia — 22; 16 Participants — p=0.28

Primary: Composite of Pregnancy-associated Hypertension and Serious Adverse Outcomes in the Mother or Fetus or Neonate — 305; 285 Participants — p=0.42

Primary: Nocturnal Blood Pressure — 128.2; 124.7; 70.6; 68.8 mmHg — p=0.45

Primary: Eating Habits Confidence Survey — 4.2; 4.5 units on a scale

Primary: Composite Adverse Perinatal Outcome — 353; 427; 272; 336 Participants — p=<0.001

Primary: Cutaneous Conductance (%Maximum) Response to Acetylcholine — 89.4; 72.5 % of maximal cutaneous conductance

Primary: Time to Achieve Non Severe Range Blood Pressure — 10; 20 minutes

Primary: Duration of Magnesium Sulfate Use in the Postpartum Period Defined as the Duration in Hours Between Delivery and Discontinuation of Magnesium Sulfate. — 21.6; 24 hours

Primary: Maternal Serum Magnesium Level at 4 Hours After Administration — 3.53; 4.41 mg/dL

Primary: Mean Arterial Blood Pressure (MAP) — 88.9; 86.8 mmHg

Primary: Positive Predictive Value of Earliest Available Platelet Count — 99; 90; 100 percentage of positive platelet counts

Primary: Persistently Elevated Blood Pressures 7 Days Postpartum — 10; 23 Participants — p=0.03

Primary: Number of Participants With Preeclampsia Diagnosis With Severe Features Based on Clinician Diagnosis — 37; 41 Participants

Primary: Change in Mean Arterial Blood Pressure (MAP) — 0; 2; 4 mmHg

Primary: The Umbilical Artery pH — 7.22; 7.20 pH — p=.38

Primary: Difference in Systolic Blood Pressure (SBP) — 131.8; 132.0; 129.1; 129.1 mmHg

Primary: Detection of Fluid in the Lungs — 2; 3 Participants — p=.162

Primary: Number of Participants With Adverse Events — 2; 0 participants

Primary: Average Mean Arterial Blood Pressure- Mild Group — 93; 93 mmHg

Primary: Percent of Participants Eligible, Enrolled and Retained (Feasibility) — 61 Participants

Primary: Pregnancy Loss or NICU Admission for Greater Than 48 Hours — 155; 150 participants